進修

2000美國加州勞倫斯柏克萊國家實驗室

2005-2006美國波士頓布萊根和婦女醫院病理部

2010美國馬里蘭州美國國家癌症研究所

教職

1991-1998國立陽明大學醫學系內科助教

1998-2004國立陽明大學醫學系內科講師

2004-2012國立陽明大學醫學系內科助理教授

2012-2016國立陽明大學醫學系內科副教授

2016-迄今 國立陽明大學醫學系內科教授

專科醫師

1995-迄今 內科專科醫師

1996-迄今 腫瘤內科專科醫師

1998-迄今 血液病專科醫師

2007-迄今 癌症安寧緩和專科醫師

2008-迄今 血液及骨髓造血幹細胞移植專科醫師

專科學會會員

美國癌症醫學研究學會

美國臨床腫瘤學會

台灣內科醫學會

中華民國癌症醫學會

中華民國血液病學會

中華民國血液及骨髓移植學會

台灣癌症安寧緩和醫學會

台灣安寧緩和醫學學會

專科學會任職

2015~2019  中華民國癌症醫學會理事

2019~2021  中華民國癌症醫學會監事

2017~迄今 中華民國癌症醫學會腫瘤內科專科醫師甄審委員

2008~迄今 中華醫學會雜誌助理編輯

專長

惡性肉瘤、膀胱癌、大腸癌與食道癌的臨床與基礎研究; 癌症臨床試驗; 癌症基因之研究;癌症免疫治療

《近期研究著作2014~2023 》

1. Hsu PK, Chen HY, Yeh YC, Yen CC, Wu YC, Hsu CP, Hsu WH, Chou TY. TPX2 expression is associated with cell proliferation and patient outcome in esophageal squamous cell carcinoma. J Gastroenterol. 2014 Aug;49(8):1231-40.
2. Hsu PK, Kao HL, Chen HY, Yen CC, Wu YC, Hsu WH, Chou TY. Loss of CRNN expression is associated with advanced tumor stage and poor survival in patients with esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2014 May;147(5): 1612-1618
3. Liu YC, Gau JP, Yu YB, Hong YC, Yen CC, Liu CY, Chao TC, Hsiao LT, Liu JH, Chiou TJ, Tzeng CH. Prognostic Factors and Treatment Efficacy in Patients with Primary Diffuse Large B-cell Lymphoma of the Bone: Single Institute Experience Over 11 Years. Intern Med. 2014;53(2):95-101.
4. Yen CC, Hsiao CD, Chen WM, Wen YS, Lin YC, Chang TW, Yao FY, Hung SC, Wang JY, Chiu JW, Wang HW, Lin CH, Chen TH, Chen P CH, Liu CL, Tzeng CH, Fletcher JA. Cytotoxic effects of 15d-PGJ2 against osteosarcoma through ROS-mediated AKT and cell cycle inhibition. Oncotarget. 2014 Feb 15;5(3):716-25.
5. Wang HW, Yang SH, Huang GD, Lin JK, Chen WS, Jiang JK, Lan YT, Lin CC, Hwang WL, Tzeng CH, Li AF, Yen CC, Teng HW. Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism. J Cancer Res Clin Oncol. 2014 Apr;140(4):561-71.
6. Hung GY, Horng JL, Yen HJ, Yen CC, Chen WM, Chen PC, Wu HT, Chiou HJ. Incidence Patterns of Primary Bone Cancer in Taiwan (2003-2010): A Population-Based Study. Ann Surg Oncol. 2014 2014 Aug;21(8):2490-8
7. Wang JY, Wu PK, Chen PC, Yen CC, Hung GY, Chen CF, Hung SC, Tsai SF, Liu CL, Chen TH, Chen WM. Manipulation therapy prior to diagnosis induced primary osteosarcoma metastasis-from clinical to basic research. PLoS One. 2014 May 7;9(5):e96571
8. Yeh CN, Yen CC,* Chen YY, Cheng CT, Huang SC, Chang TW, Yao FY, Lin YC, Wen YS, Chiang KC, Chen JS, Yeh TS, Tzeng CH, Chao TC, Fletcher JA. Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors. Oncotarget. 2014 June 30;5(12): 4071-4086
9. Yang YH, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, Lan YT, Lin CC, Yen CC, Tzeng CH, Teng HW. Comparison of cetuximab to bevacizumab as the first-line bio-chemotherapy for patients with metastatic colorectal cancer: Superior progression-free survival is restricted to patients with measurable tumors and objective tumor response-a retrospective study. J Cancer Res Clin Oncol. 2014 Nov;140(11):1927-36
10. Chen CH, Lin DS, Cheng CW, Lin CJ, Lo YK, Yen CC, Lee AY, Hsiao CD. Cdc6 cooperates with c-Myc to promote genome instability and epithelial to mesenchymal transition EMT in zebrafish. Oncotarget. 2014 Aug 15;5(15):6300-11.
11. Hsueh YS, Chang HH, Chiang NJ, Yen CC, Li CF, Chen LT. MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors. Oncotarget. 2014 Nov 30;5(22):11723-36.
12. Chen KF, Yen CC, Lin JK, Chen WS, Yang SH, Jiang JK, Lan YT, Lin CC, Yu HC, Hsu HM, Lin WL, Teng HW. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy. BMC Cancer. 2015 Apr 17;15:301.
13. Hung GY, Yen HJ, Yen CC, Chen WM, Chen PC, Wu HT, Chiou HJ, Chang WH, Hsu HE. Experience of Pediatric Osteosarcoma of the Extremity at a Single Institution in Taiwan: Prognostic Factors and Impact on Survival. Ann Surg Oncol. 2015 Apr;22(4):1080-7.
14. Chen MH, Yen CC, Cheng CT, Wu RC, Huang SC, Yu CS, Chung YH, Liu CY, Chang PM, Chao Y, Chen MH, Chen YF, Chiang KC, Yeh TS, Chen TC, Huang CF, Yeh CN. Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. Oncotarget. 2015 Sep 15;6(27):23594-608.
15. Lee YT, Liu CJ, Hu YW, Teng CJ, Tzeng CH, Yeh CM, Chen TJ, Lin JK, Lin CC, Lan YT, Wang HS, Yang SH, Jiang JK, Chen WS, Lin TZ, Chang SC, Chen MH, Teng WH, Liu JH, Yen CC.* Incidence of second primary malignancies following colorectal cancer: A distinct pattern of occurrence between colon and rectal cancers and association of co-morbidity with second primary malignancies in a population-based cohort of 98,876 patients in Taiwan. Medicine (Baltimore). 2015 Jul;94(26):e1079
16. Hung GY, Yen CC,* Horng JL, Liu CY, Chen WM, Chen TH, Liu CL. Incidences of Primary Soft Tissue Sarcoma Diagnosed on Extremities and Trunk Wall: A Population-Based Study in Taiwan. Medicine (Baltimore). 2015 Oct;94(41):e1696
17. Chou YS, Liu CY, Chang YH, King KL, Chen PC, Pan CC, Shen SH, Liu YM, Lin AT, Chen KK, Shyr YM, Lee RC, Chao TC, Yang MH, Chan CH, You JY, Yen CC.* Prognostic factors of primary resected retroperitoneal soft tissue sarcoma: Analysis from a single Asian tertiary center and external validation of Gronchi's nomogram.. J Surg Oncol. 2016 Mar;113(4):355-60.
18. Chou YS, Yen CC,* Chen WM, Lin YC, Wen YS, Ke WT, Wang JY, Liu CY, Yang MH, Chen TH, Liu CL. Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel. Int J Oncol. 2016 Mar;48(3):1187-94
19. Hung GY, Yen HJ, Yen CC,* Wu PK, Chen CF, Chen PC, Wu HT, Chiou HJ, Chen WM. Improvement in High-Grade Osteosarcoma Survival: Results from 202 Patients Treated at a Single Institution in Taiwan. Medicine (Baltimore). 2016 Apr;95(15):e3420
20. Lee CY, Yen CC, Yen HJ, Shiau CY, Chao TC, Wu PK, Chen CF, Chen PC, Wu HT, Chiou HJ, Chen CC, Hung GY, Chen WM. Outcomes of 50 Patients With Ewing Sarcoma Family of Tumors Treated at a Single Institution in Taiwan. Medicine (Baltimore). 2016 May;95(22):e3830.
21. Tsai YJ, Lin JK, Chen WS, Jiang JK, Teng HW, Yen CC, Lin TC, Yang SH. Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough? Springerplus. 2016 Aug 11;5(1):1318.
22. Wu CY, Chiou TJ, Liu CY, Lin FC, Lin JS, Hung MH, Hsiao LT, Yen CC, Gau JP, Yen HJ, Hung GY, Hsu HC, Tzeng CH, Liu JH, Yu YB. Decision-tree algorithm for optimized hematopoietic progenitor cell-based predictions in peripheral blood stem cell mobilization. Transfusion. 2016 Aug;56(8):2042-51
23. Yeh CN, Chen MH, Chen YY, Yang CY, Yen CC, Tzen CY, Chen LT, Chen JS. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. Oncotarget. 2017 Jul 4;8(27):44121-44130
24. Chen JS, Yeh CN, Cheng CT, Yen CC,* Chen YY, Huang SC, Chiang KC, Yeh TS, Chen SC, Chao TC, Yang MH, Chao Y.  Role of PLK1 signaling pathway genes in gastrointestinal stromal tumors. Oncol Lett. 2018 Sep;16(3):3070-3082
25. Yen CC, Chen TW. Next frontiers in systemic therapy for soft tissue sarcoma. Chin Clin Oncol. 2018 Aug;7(4):43
26. Hung GY, Horng JL, Chen PC, Lin LY, Chen JY, Chuang PH, Chao TC, Yen CC.* Incidence of soft tissue sarcoma in Taiwan: A nationwide population-based study (2007-2013). Cancer Epidemiol. 2019 Jun;60:185-192
27. Yen CC, Chen LT, Li CF, Chen SC, Chua WY, Lin YC, Yen CH, Chen YC, Yang MH, Chao Y, Fletcher JA. Identification of phenothiazine as an ETV1‑targeting agent in gastrointestinal stromal tumors using the Connectivity Map. Int J Oncol. 2019 Aug;55(2):536-546.
28. Yen CC, Chen SC, Hung GY, Wu PK, Chua WY, Lin YC, Yen CH, Chen YC, Wang JY, Yang MH, Chao Y, Chang MC, Chen WM. Expression profile‑driven discovery of AURKA as a treatment target for liposarcoma. Int J Oncol. 2019 Oct;55(4):938-948.
29. Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. Lancet Oncol. 2019 Nov;20(11):1506-1517.
30. Chen PC, Yen CC, Hung GY, Pan CC, Chen WM. Gene amplification and tumor grading in parosteal osteosarcoma. J Chin Med Assoc. 2019 Dec;82(12):889-894.
31. Tap WD, Wagner AJ, Schöffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo KN, Yen CC, Abdul Razak AR, Spira A, Kawai A, Le Cesne A, Van Tine BA, Naito Y, Park SH, Fedenko A, Pápai Z, Soldatenkova V, Shahir A, Mo G, Wright J, Jones RL; ANNOUNCE Investigators. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas The ANNOUNCE Randomized Clinical Trial. JAMA. 2020 Apr 7;323(13):1266-1276
32. Kanesvaran R, Porta C, Wong A, Powles T, Ng QS, Schmidinger M, Ye D, Malhotra H, Miura Y, Lee JL, Chong FLT, Pu YS, Yen CC, Saad M, Lee HJ, Kitamura H, Bhattacharyya GS, Curigliano G, Poon E, Choo SP, Peters S, Lim E, Yoshino T, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. ESMO Open 2021 Dec;6(6):100304.
33. Hsu PK, Chien LI, Huang CS, Yeh YC, Huang PI, Chen MH, Chen SY, Yen CC, Hsu HS. Treatment Patterns and Outcomes in Patients with Esophageal Cancer: An Analysis of a Multidisciplinary Tumor Board Database. Ann Surg Oncol 2022;29(1):572-585
34. Okada M, Kato K, Cho BC, Takahashi M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Matsumura Y, Takazawa A, Kitagawa Y. Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3). Clin Cancer Res. 2022 Aug 2;28(15):3277-3286.
35. Lin LC, Huang WK, Yen CC, Yang CY, Sung MT, Wong SMN, Chua DTT, Lee SWM, Chen JS, Yeh CN. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience. Front Oncol. 2022 Jun 29;12:883399.
36. Kanesvaran R, Castro E, Wong A, Fizazi K, Chua MLK, Zhu Y, Malhotra H, Miura Y, Lee JL, Chong FLT, Pu YS, Yen CC, Saad M, Lee HJ, Kitamura H, Prabhash K, Zou Q, Curigliano G, Poon E, Choo SP, Peters S, Lim E, Yoshino T, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. ESMO Open. 2022 Aug;7(4):100518
37. Chen TW, Hsu CL, Hong RL, Lee JC, Chang K, Yu CW, Chen SC, Guo JC, Chen ML, Hsu MC, Kung TF, Cheng AL, Yen CC.* A Single-Arm Phase Ib/II Study of Lenvatinib Plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma. Clin Cancer Res. 2022 Dec 1;28(23):5058-5065